Matches in SemOpenAlex for { <https://semopenalex.org/work/W2563483539> ?p ?o ?g. }
- W2563483539 endingPage "2547" @default.
- W2563483539 startingPage "2547" @default.
- W2563483539 abstract "Abstract Introduction: In the international, multicenter phase 3 APEX trial, 669 patients (pts) with multiple myeloma (MM) who had relapsed after 1–3 prior therapies were randomized to receive bortezomib (VELCADE®) 1.3 mg/m2 IV d 1, 4, 8, 11 q3wk for 8 cycles followed by 3 cycles on d 1, 8, 15, 22 q5wk, or dexamethasone (Dex) 40 mg PO d 1–4, 9–12, 17–20 q5wk for 4 cycles followed by 5 cycles on d 1–4 q4wk. Pts refractory to Dex were excluded, and those with progressive disease on Dex were eligible to cross over to bortezomib. Pts receiving bortezomib achieved significant improvement in time to progression (TTP, primary end point), response rate (CR + PR using EBMT criteria), and survival (Richardson. NEJM.2005;352:2487), which resulted in early closure of the trial. The duration of response (DOR) was longer with bortezomib, and infections ≥ grade 3, time to skeletal events, grade 4 adverse events (AE), serious AE, and discontinuations due to AE were similar in the 2 treatment arms. Methods: In this analysis, updated response rates, time to response (TTR), DOR, survival, and TTP are presented after extended follow-up. A matched-pairs analysis comparing survival and TTP of pts on bortezomib in APEX with those in another trial of MM pts who received bortezomib after Dex will also be presented. Results: 669 pts received a median of 7 cycles of therapy. Based on a median follow-up of 15.8 months, the median TTP, 1-year and overall survival (OS), response rates, median TTR, and median DOR for pts receiving bortezomib are shown in the table. Median duration of therapy for responders (CR + PR) was 7.2 months. Improved response with longer therapy (after cycle 6) was observed in 76 pts (56% of responders) in the bortezomib arm (20 pts improved from MR or PR to CR, and 56 pts improved from MR to PR). Furthermore, 28 of 135 responders (21%) achieved first response (CR/PR) after cycle 4, including 18 pts (13%) on or after cycle 6, and 10 pts (7%) on or after cycle 8. OS increased substantially with more follow-up. Median TTR was more rapid, and median DOR was longer in pts achieving CR and near CR than in those with PR. Conclusion: Updated TTP, response rates, survival, TTR, and DOR for the bortezomib group continue to support the findings of the original analysis. Thus, the clinical benefits of single-agent bortezomib in pts with relapsed MM remain robust after extended follow-up, supporting its early use in relapsed MM and its further study in the treatment of newly diagnosed disease. Efficacy Bortezomib (n = 333) Median TTP, mo 6.2 1-year survival, % 80 Median OS, mo 25.4 Response rate, % (n/N) 43 (135/315) CR 9 (27/315) PR 34 (108/315) -near CR 7 (21/315) Median TTR, mo (range) 1.4 (0.5–6.0) CR 0.8 (0.5–4.0) PR 1.4 (0.5–6.0) -near CR 0.8 (0.6–2.4) Median DOR, mo 7.8 CR 9.9 PR 7.6 -near CR 11.5" @default.
- W2563483539 created "2017-01-06" @default.
- W2563483539 creator A5002061358 @default.
- W2563483539 creator A5002972322 @default.
- W2563483539 creator A5018139001 @default.
- W2563483539 creator A5020123690 @default.
- W2563483539 creator A5023276777 @default.
- W2563483539 creator A5029801761 @default.
- W2563483539 creator A5031837957 @default.
- W2563483539 creator A5032464400 @default.
- W2563483539 creator A5034783996 @default.
- W2563483539 creator A5038099312 @default.
- W2563483539 creator A5043490010 @default.
- W2563483539 creator A5043526996 @default.
- W2563483539 creator A5047235687 @default.
- W2563483539 creator A5047272364 @default.
- W2563483539 creator A5048985421 @default.
- W2563483539 creator A5056492087 @default.
- W2563483539 creator A5058183811 @default.
- W2563483539 creator A5071589084 @default.
- W2563483539 creator A5074839025 @default.
- W2563483539 date "2005-11-16" @default.
- W2563483539 modified "2023-10-16" @default.
- W2563483539 title "Bortezomib Continues Demonstrates Superior Efficacy Compared with High-Dose Dexamethasone in Relapsed Multiple Myeloma: Updated Results of the APEX Trail." @default.
- W2563483539 doi "https://doi.org/10.1182/blood.v106.11.2547.2547" @default.
- W2563483539 hasPublicationYear "2005" @default.
- W2563483539 type Work @default.
- W2563483539 sameAs 2563483539 @default.
- W2563483539 citedByCount "26" @default.
- W2563483539 countsByYear W25634835392014 @default.
- W2563483539 countsByYear W25634835392019 @default.
- W2563483539 countsByYear W25634835392020 @default.
- W2563483539 crossrefType "journal-article" @default.
- W2563483539 hasAuthorship W2563483539A5002061358 @default.
- W2563483539 hasAuthorship W2563483539A5002972322 @default.
- W2563483539 hasAuthorship W2563483539A5018139001 @default.
- W2563483539 hasAuthorship W2563483539A5020123690 @default.
- W2563483539 hasAuthorship W2563483539A5023276777 @default.
- W2563483539 hasAuthorship W2563483539A5029801761 @default.
- W2563483539 hasAuthorship W2563483539A5031837957 @default.
- W2563483539 hasAuthorship W2563483539A5032464400 @default.
- W2563483539 hasAuthorship W2563483539A5034783996 @default.
- W2563483539 hasAuthorship W2563483539A5038099312 @default.
- W2563483539 hasAuthorship W2563483539A5043490010 @default.
- W2563483539 hasAuthorship W2563483539A5043526996 @default.
- W2563483539 hasAuthorship W2563483539A5047235687 @default.
- W2563483539 hasAuthorship W2563483539A5047272364 @default.
- W2563483539 hasAuthorship W2563483539A5048985421 @default.
- W2563483539 hasAuthorship W2563483539A5056492087 @default.
- W2563483539 hasAuthorship W2563483539A5058183811 @default.
- W2563483539 hasAuthorship W2563483539A5071589084 @default.
- W2563483539 hasAuthorship W2563483539A5074839025 @default.
- W2563483539 hasConcept C121332964 @default.
- W2563483539 hasConcept C126322002 @default.
- W2563483539 hasConcept C141071460 @default.
- W2563483539 hasConcept C142424586 @default.
- W2563483539 hasConcept C197934379 @default.
- W2563483539 hasConcept C203092338 @default.
- W2563483539 hasConcept C2776364478 @default.
- W2563483539 hasConcept C2776694085 @default.
- W2563483539 hasConcept C2777478702 @default.
- W2563483539 hasConcept C2778822529 @default.
- W2563483539 hasConcept C2780401358 @default.
- W2563483539 hasConcept C535046627 @default.
- W2563483539 hasConcept C71924100 @default.
- W2563483539 hasConcept C87355193 @default.
- W2563483539 hasConcept C90924648 @default.
- W2563483539 hasConceptScore W2563483539C121332964 @default.
- W2563483539 hasConceptScore W2563483539C126322002 @default.
- W2563483539 hasConceptScore W2563483539C141071460 @default.
- W2563483539 hasConceptScore W2563483539C142424586 @default.
- W2563483539 hasConceptScore W2563483539C197934379 @default.
- W2563483539 hasConceptScore W2563483539C203092338 @default.
- W2563483539 hasConceptScore W2563483539C2776364478 @default.
- W2563483539 hasConceptScore W2563483539C2776694085 @default.
- W2563483539 hasConceptScore W2563483539C2777478702 @default.
- W2563483539 hasConceptScore W2563483539C2778822529 @default.
- W2563483539 hasConceptScore W2563483539C2780401358 @default.
- W2563483539 hasConceptScore W2563483539C535046627 @default.
- W2563483539 hasConceptScore W2563483539C71924100 @default.
- W2563483539 hasConceptScore W2563483539C87355193 @default.
- W2563483539 hasConceptScore W2563483539C90924648 @default.
- W2563483539 hasIssue "11" @default.
- W2563483539 hasLocation W25634835391 @default.
- W2563483539 hasOpenAccess W2563483539 @default.
- W2563483539 hasPrimaryLocation W25634835391 @default.
- W2563483539 hasRelatedWork W1991948976 @default.
- W2563483539 hasRelatedWork W2027348595 @default.
- W2563483539 hasRelatedWork W2063424779 @default.
- W2563483539 hasRelatedWork W2104706142 @default.
- W2563483539 hasRelatedWork W2104965094 @default.
- W2563483539 hasRelatedWork W2124503326 @default.
- W2563483539 hasRelatedWork W2377458274 @default.
- W2563483539 hasRelatedWork W2409439928 @default.
- W2563483539 hasRelatedWork W3028919400 @default.
- W2563483539 hasRelatedWork W3029266790 @default.
- W2563483539 hasVolume "106" @default.
- W2563483539 isParatext "false" @default.